Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 43-year-old male patient with alopecia totalis successfully regaining all his hair after six months of treatment with tofacitinib, with no relapse observed after one year.

This study found that Rumex japonicas Houttuyn ethanol extract may promote hair growth and protect against oxidative stress-induced hair damage in mice and HaCaT cells.

This study explored using 3D models derived from reflectance confocal microscopy to better understand and differentiate melanoma on sun-damaged skin, suggesting enhanced diagnostic possibilities.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

In in-vitro experiments, this study found that poncirin showed higher inhibitory activity against JAK3 than tofacitinib, suggesting potential for alopecia areata treatment.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

This study suggests that oral JAK inhibitors can be an effective treatment option for approximately half of patients with moderate to severe alopecia areata, despite variable responses and potential adverse effects.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

This study found that JAK1 and JAK3 inhibitors effectively reversed alopecia in a mouse model of AA by reducing skin inflammation, while JAK2 inhibition did not promote hair regrowth.

Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.

This study reported that oral JAK inhibitors, tofacitinib and ruxolitinib, may effectively promote hair regrowth in alopecia areata patients, though ruxolitinib had fewer adverse events compared to tofacitinib.

This study identified a specific subset of macrophages as a key source of oncostatin M, maintaining hair follicle stem cell quiescence during the resting phase in mice, suggesting a potential target for treating hair disorders.

This study found that both ruxolitinib and tofacitinib were effective in promoting hair regrowth for patients with severe alopecia areata, with no significant difference in efficacy and relapse rate between them, and both were well tolerated throughout the treatment.

This study predicted that 6-hydroxy genistein, coreximine, and scoulerine from Dadap leaves may act as anti-alopecia agents by interacting with JAK2, but further in-vivo testing is needed.

This study found that knocking out STAT5 expression in specific mouse hair follicles after tamoxifen treatment initiated uniform hair growth, highlighting STAT5's role in regulating the hair growth cycle.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

This study found that secreted factors from skin-derived precursors, especially those pre-treated with jasmine extract, enhanced keratinocyte growth and influenced reconstructed human epidermis thickness in lab experiments.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This study found that inhibiting JAK signaling can unexpectedly trigger hair growth in resting-phase mouse skin, implicating JAK-STAT pathways and oncostatin M in maintaining hair follicle stem cell quiescence.

This study concluded that the ethanolic extract of Eugenia jambolana fruit pulp significantly promoted hair growth in albino mice compared to the seeds extract.

In a mouse study, JAK inhibitors like Jakafi and Xeljanz prevented alopecia areata and aided hair regrowth; similar effects were observed in three patients with the condition.

This educational activity reports no new research findings; it aims to help physicians assess and improve their clinical skills through self-evaluation and continued medical education.

In this study, permanent waving treatments, especially those using lotion B and repeated procedures, were found to significantly damage hair protein content and physical properties.

This article discusses new guidelines recommending finasteride for asymptomatic men during prostate cancer screening to reduce disease risk, but notes no impact on mortality; it reports no new results.

This journal summarizes advancements in plastic and reconstructive surgery techniques, including maxillofacial reconstruction and cosmetic procedures, but reports no new research results.

This article shares personal observations from attending the Japanese Society for Hair Restoration meeting, with no new empirical results reported.

This article provides a biography of Dr. James E. Vogel, focusing on his career in hair restoration surgery, but it includes no new research findings.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

This study found that the 3' UTR of JAM-A acts as a key competing endogenous RNA that supports dermal papilla cell function and hair follicle regeneration in alopecia areata.

This article poses the question of whether Janus kinase (JAK) inhibitors are beneficial for treating androgenic alopecia, but it does not provide results or conclusions from any study.